Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 3
Submit an article Journal homepage
221
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax

Anna ChristoforidouDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, GreeceCorrespondence[email protected]
,
Zoe BezirgiannidouDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece
,
George VrachioliasDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece
,
Menelaos PapoutselisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece
,
Emmanouil SpanoudakisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece
&
Ιoannis KotsianidisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece
Pages 749-752 | Received 15 Jul 2019, Accepted 24 Oct 2019, Published online: 12 Nov 2019

References

  • Dearden C. B- and T-cell prolymphocytic leukemia: antibody approaches. Hematology Am Soc Hematol Educ Program. 2012;2012:645–651.
  • Dearden C. Management of prolymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015(1):361–367.
  • Campo EME, Montserrat E, Harris NL, et al. editor. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2017. p. 222–223.
  • Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood. 1997;89(6):2015–2023.
  • Chapiro E, Roos-Weil D, Bougacha N, et al. Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group. Blood. 2018;132(Suppl 1):943–943.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Dohner H, Ho AD, Thaler J, et al. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst. 1993;85(8):658–662.
  • Del Giudice I, Osuji N, Dexter T, et al. B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia. 2009;23(11):2160–2167.
  • Gordon MJ, Raess PW, Young K, et al. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. Br J Haematol. 2017;179(3):501–503.
  • Damlaj M, Al Balwi M, Al Mugairi AM. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. Leuk Lymphoma. 2018;59(3):739–742.
  • Eyre TA, Fox CP, Shankara P, et al. Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia. Br J Haematol. 2017;177(3):486–491.
  • Coelho H, Badior M, Melo T. Sequential kinase inhibition (idelalisib/ibrutinib) induces clinical remission in B-cell prolymphocytic leukemia harboring a 17p deletion. Case Rep Hematol. 2017;2017:8563218.
  • Patil N, Went RG. Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors. Br J Haematol. 2019;186(4):e80–e82.
  • Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342–353.
  • Huang S, Jiang C, Guo H, et al. Resistance mechanisms underlying venetoclax resistance in mantle cell lymphoma. Blood. 2017;130(Suppl 1):2749–2749.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.